Reify Health, a Boston, MA-based provider of solutions that empower the clinical trial ecosystem, raised $220M in Series D funding at a $4.8 Billion valuation.
The round was co-led by Altimeter Capital and Coatue, joined by Dragoneer Investment Group and existing investors ICONIQ Growth, Adams Street, and Battery Ventures.
The company intends to use the funds to accelerate efforts to improve diversity and representation in clinical trial participation.
Led by Ralph Passarella, CEO, Reify Health operates StudyTeam and Care Access, to provide trial optimization software and transformative clinical trial infrastructure that delivers research directly to more healthcare providers, communities, and patients wherever they are through partnerships with top biopharma companies, thousands of research clinics worldwide, and healthcare & community organizations.
Reify Health is launching BRIDGE (Bringing Representation, Inclusion, and Diversity to Global Enrollment), an initiative aimed at devoting the company’s capabilities in partnership with like-minded organizations to achieve two primary objectives:
- Build a robust understanding, both qualitative and quantitative, of the barriers to underrepresented minority groups participating in clinical trials.
- Deliver solutions that overcome these barriers, so clinical trials are more representative of the patient populations they aim to treat.
FinSMEs
21/04/2022